Soligenix, Inc. (SNGX)

Market Cap	4.03M
Revenue (ttm)	839,359
Net Income (ttm)	-6.14M
Shares Out	10.52M
EPS (ttm)	-0.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	491,668
Open	0.406
Previous Close	0.400
Day's Range	0.382 - 0.406
52-Week Range	0.370 - 4.200
Beta	1.85
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2024

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inf...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 15, 1987
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: SNGX

Financial Performance

In 2023, Soligenix's revenue was $839,359, a decrease of -11.55% compared to the previous year's $948,911. Losses were -$6.14 million, -55.50% less than in 2022.